Medigene Showcases Optimal T Cell Receptor Use at Cell 2024

Planegg/Martinsried, November 8, 2024. Medigene AG, an oncology-focused company, has showcased significant improvements in its proprietary End-to-End Platform for developing advanced T cell receptors (TCRs) at the Cell 2024 Conference held by Oxford Global in London, UK, from November 6-8, 2024. The company's efforts are directed towards creating TCRs that are safe, sensitive, and specific, suitable for various therapeutic applications, including TCR-engineered T cells (TCR-T), TCR-guided T cell engagers (TCR-TCEs), and TCR-natural killer cell therapies (TCR-NK).

During the event, Medigene's management team, including Prof. Dolores Schendel, Chief Scientific Officer, and Kirsty Crame, MD, Vice President, Clinical Strategy & Development, shared their insights. Kirsty Crame participated in a panel discussion on "Exploring Autologous vs. Allogeneic Therapies," addressing clinical perspectives, patient considerations, key immunological factors, and manufacturing hurdles associated with each therapeutic approach. Additionally, Crame delivered a keynote address titled "Making the Ordinary Extraordinary: MDG1015 A Clinic Ready 3rd Generation TCR-T Therapy." This comprehensive presentation provided an overview of MDG1015, a pioneering third-generation TCR-T therapy targeting NY-ESO-1/LAGE-1a, a well-validated cancer-testis antigen found in various tumors. MDG1015 received Investigational New Drug (IND) approval in the third quarter of 2024 and is set for a Clinical Trial Application (CTA) filing in the fourth quarter of 2024.

Prof. Dolores Schendel presented on the "TCR-T Platform for Solid Tumors," discussing Medigene's End-to-End Platform, which offers advanced technologies for developing 3S TCRs. These tools ensure high specificity, sensitivity, and safety for precise tumor targeting. The platform also includes technologies that enhance TCR-T cells' performance within the challenging environments of solid tumors. Schendel highlighted innovative tagging and tracing tools that allow for seamless tracking of 3S TCRs across all research and clinical development phases.

Medigene AG, listed on the Prime Standard of the Frankfurt Stock Exchange (FSE: MDG1), is a leading immuno-oncology company dedicated to developing T cell receptor (TCR)-guided therapies to combat cancer effectively. The company's End-to-End Platform generates superior 3S T cell receptors utilized in various therapeutic modalities, including TCR-engineered T cell therapies, TCR-guided T cell engager therapies, and TCR-natural killer cell therapies. These therapies are developed for both in-house products and partnerships.

Medigene's leading TCR-T program, MDG1015, targets multiple solid tumor indications and aims to be a best-in-class therapy. The company's platform technologies enhance T cells to overcome the immunosuppressive tumor microenvironment, ensuring that the T cell drug product composition maximizes safety, efficacy, and durability of response. MDG1015 received IND approval in the third quarter of 2024 and is preparing for a CTA filing in the fourth quarter of 2024.

Medigene's comprehensive End-to-End Platform harnesses the power of natural T cell receptors, combining them with various immune system components to form highly specific, sensitive, and safe therapeutic modalities. The platform integrates sophisticated TCR generation and optimization techniques and features advanced product armoring and enhancement technologies. These technologies include PD1-41BB and CD40L-CD28 Costimulatory Switch Proteins, and iM-TCR. Medigene's collaborations with notable partners such as BioNTech, Regeneron, and WuXi Biologics further highlight the platform's capabilities and its potential to revolutionize cancer treatment.

Medigene AG continues to advance its mission of developing innovative T cell receptor-guided therapies to provide effective cancer treatments, leveraging its proprietary End-to-End Platform to achieve this goal.